Expansion into personalized cancer medicine
First written in FY2016. 16 of 26 entries say "Restated". Latest entry: 2026-08-28.
1 other company's latest entry also says "Advanced".
- FY2026-H1RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and business operations involving large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-genome sequencing, neoantigen analysis, and neoantigen dendritic cell therapy, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will continue developing the new cancer gene panel test and conducting research into new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues research into genetic and immune analysis services, the new cancer gene panel test, and personalized cancer immunotherapies. - FY2025RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and business operations involving large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-genome sequencing, neoantigen analysis, and neoantigen dendritic cell therapy, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will continue developing the new cancer gene panel test and conducting research into new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of genetic and immune analysis services, development of the new cancer gene panel test, and research into personalized cancer immunotherapies. - FY2024-Q3AdvancedAnnual report
「For the time being, we will focus on developing this new cancer gene panel test as a development pipeline intended for covered medical care, aiming to launch it as soon as possible.」
The company has stated its policy of prioritizing and focusing on the new cancer gene panel test as its near-term development pipeline in cancer precision medicine, with the aim of launching it. - FY2024-Q1AdvancedAnnual report
「We will also continue to consider partnerships with companies engaged in the manufacture and sale of medical devices, with the aim of obtaining health insurance coverage.」
A specific measure has been added to pursue partnerships with medical device manufacturers and distributors in order to obtain health insurance coverage for the new cancer gene panel test. - FY2023AdvancedAnnual report
「We have also begun developing a new panel and testing method for analyzing cancer genes by liquid biopsy that can be performed under coverage by health insurance (the "new cancer gene panel test").」
As part of its cancer precision medicine initiatives, the company has announced the start of development of a new cancer gene panel test, targeting its use under health insurance coverage for early detection, treatment selection, and recurrence monitoring. - FY2023-Q3RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-exome sequencing, RNA sequencing, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple genetic and immune analysis services and research and development of personalized cancer immunotherapies. - FY2023-Q1RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-exome sequencing, RNA sequencing, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple analysis services and research and development of personalized cancer immunotherapies. - FY2022-Q3RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-exome sequencing, RNA sequencing, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple analysis services and research and development of personalized cancer immunotherapies. - FY2022-Q1RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-exome sequencing, RNA sequencing, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple analysis services and research and development of personalized cancer immunotherapies. - FY2021-Q3RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-exome sequencing, RNA sequencing, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple analysis services and research and development of personalized cancer immunotherapies. - FY2021-Q2RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-exome sequencing, RNA sequencing, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple analysis services and research and development of personalized cancer immunotherapies. - FY2021-Q1RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of large-scale cancer genomic testing and other analysis services, including detailed genetic analysis of cancer cells such as whole-exome sequencing, RNA sequencing, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple analysis services and research and development of personalized cancer immunotherapies. - FY2020-Q3RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of analysis services, including detailed genetic analysis of cancer cells such as whole-exome analysis, RNA sequencing analysis, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple analysis services and research and development of personalized cancer immunotherapies. - FY2020-Q2RestatedAnnual report
「In the cancer precision medicine-related business, in addition to joint research and commercialization of analysis services, including detailed genetic analysis of cancer cells such as whole-exome analysis, RNA sequencing analysis, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of analysis services and research and development of personalized cancer immunotherapies. - FY2020-Q1RestatedAnnual report
「In addition to joint research and commercialization of analysis services, including detailed genetic analysis of cancer cells such as whole-exome analysis, RNA sequencing analysis, and neoantigen analysis, liquid biopsy for the early detection of cancer cells in the blood, TCR/BCR repertoire analysis, and immune response analysis, we will advance research and development of new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues joint research and commercialization of multiple analysis services and research and development of neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy in cancer precision medicine. - FY2018AdvancedAnnual report
「In addition to the research and development of pharmaceuticals and related businesses, we began full-scale operations in the cancer precision medicine-related business during the current fiscal year.」
The cancer precision medicine-related business through CPM began full-scale operations during the current fiscal year and advanced to the stage of developing analysis services and conducting research into personalized immunotherapies as businesses. - FY2018-Q3AdvancedAnnual report
「After confirming the results of this joint research, liquid biopsy is scheduled to be applied clinically for cancer diagnosis at the medical institutions of the IMS Group. CPM and the IMS Group's medical institutions will also continue to pursue broad partnerships in cancer precision medicine, including clinical sequencing for analyzing the genes of individual cancer patients.」
The planned clinical application of liquid biopsy based on the results of joint research with the IMS Group, together with a broad partnership policy, has taken concrete shape in cancer precision medicine. - FY2018-Q2AdvancedAnnual report
「The establishment of CPM is expected to create synergies between the company and TE in comprehensive cancer genomic analysis and cancer immunology, further accelerating cancer precision medicine.」
The concrete organizational foundations for cancer precision medicine, including the establishment of CPM, the joint venture with TE, and the transfer of the business, have advanced to the implementation stage. - FY2018-Q1AdvancedAnnual report
「The establishment of CPM is expected to create synergies between the company and TE in comprehensive cancer genomic analysis and cancer immunology, further accelerating cancer precision medicine.」
The establishment of CPM and collaboration with TE have established a concrete organizational and partnership platform for creating synergies in comprehensive cancer genomic analysis and cancer immunology and accelerating the business in cancer precision medicine. - FY2017RestatedAnnual report
「We believe that cancer care requires "cancer precision medicine," which uses this information for prevention, early detection, selection of the optimal treatment, and development of new treatments.」
The company continues to pursue precision medicine initiatives involving prevention, diagnosis, treatment selection, and development of new treatments using genomic, epigenomic, proteomic, and other information. - FY2017-Q3RestatedAnnual report
「This technology is essential to cancer precision medicine, enabling the provision of optimal medical care for each individual patient based on genomic and other information.」
The company positions its TCR analysis service as a core technology for cancer precision medicine that provides optimal medical care for each patient. - FY2017-Q2RestatedAnnual report
「We are considering initiatives that involve analyzing various samples provided by cancer patients, including (1) recommending a suitable molecularly targeted drug if one is available, (2) monitoring for recurrence at the genetic level, and (3) recommending a vaccine therapy suited to the patient if no appropriate molecularly targeted drug exists.」
The company reiterates its precision medicine plan involving drug selection, recurrence monitoring, and vaccine referrals through sample analysis. - FY2017-Q1RestatedAnnual report
「We are considering initiatives that involve analyzing various samples provided by cancer patients, including (1) recommending a suitable molecularly targeted drug if one is available, (2) monitoring for recurrence at the genetic level, and (3) recommending a vaccine therapy suited to the patient if no appropriate molecularly targeted drug exists.」
The company continues to pursue a precision medicine plan involving drug selection, recurrence monitoring, and vaccine referrals through sample analysis. - FY2016First statedAnnual report
「We believe that cancer care requires "cancer precision medicine," which uses these innovative technologies for prevention, early detection, selection of the optimal treatment, and development of new treatments.」
A plan to provide treatment selection, recurrence monitoring, and vaccine referrals through analysis of patients' genomes, epigenomes, proteomes, and other data.